+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Dermatomyositis - Pipeline Review, H2 2019

  • ID: 4894174
  • Drug Pipelines
  • December 2019
  • Region: Global
  • 165 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Biocon Ltd
  • CSL Ltd
  • GNI Group Ltd
  • Johnson & Johnson
  • Neovacs SA
  • Octapharma AG
  • MORE
Dermatomyositis - Pipeline Review, H2 2019

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Dermatomyositis - Pipeline Review, H2 2019, provides an overview of the Dermatomyositis (Musculoskeletal Disorders) pipeline landscape.

Dermatomyositis is a rare inflammatory disease which is characterized by chronic muscle inflammation accompanied by muscle weakness. Symptoms of dermatomyositis include a distinctive skin rash, muscle weakness, and inflammatory myopathy, or inflamed muscles. Risk factors include age and gender. Treatment includes corticosteroids.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Dermatomyositis - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Dermatomyositis (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Dermatomyositis (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Dermatomyositis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 7, 4, 3, 2, 1 and 1 respectively.

Dermatomyositis (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Dermatomyositis (Musculoskeletal Disorders).
  • The pipeline guide reviews pipeline therapeutics for Dermatomyositis (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Dermatomyositis (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Dermatomyositis (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Dermatomyositis (Musculoskeletal Disorders)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Dermatomyositis (Musculoskeletal Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Dermatomyositis (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Biocon Ltd
  • CSL Ltd
  • GNI Group Ltd
  • Johnson & Johnson
  • Neovacs SA
  • Octapharma AG
  • MORE
Introduction
Report Coverage
Dermatomyositis - Overview
Dermatomyositis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Dermatomyositis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Dermatomyositis - Companies Involved in Therapeutics Development
Biocon Ltd
Bristol-Myers Squibb Co
Chugai Pharmaceutical Co Ltd
Corbus Pharmaceuticals Inc
CSL Ltd
Eli Lilly and Co
GNI Group Ltd
Hope Pharmaceuticals Inc
Johnson & Johnson
Kezar Life Sciences Inc
Neovacs SA
NovelMed Therapeutics Inc
Octapharma AG
Pfizer Inc
ReveraGen BioPharma Inc
Viela Bio Inc
Dermatomyositis - Drug Profiles
abatacept - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
baricitinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BVX-20 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
immune globulin (human) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
immune globulin (human) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KZR-616 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lenabasum - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies for Dermatomyositis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PF-06823859 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pirfenidone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sodium thiosulfate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tocilizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tofacitinib citrate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tofacitinib citrate ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ustekinumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target IFN-Alpha for Metabolic Disorders, Immunology, Infectious Diseases and Musculoskeletal Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
vamorolone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VIB-7734 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Dermatomyositis - Dormant Projects
Dermatomyositis - Discontinued Products
Dermatomyositis - Product Development Milestones
Featured News & Press Releases
Jun 12, 2019: Lenabasum open-label extension data to be presented at EULAR 2019 continue to show a favorable safety profile and improvement in efficacy outcomes in Systemic Sclerosis and Dermatomyositis Phase 2 Studies
Apr 01, 2019: Neovacs announces an agreement with Biosyn to diversify its supply of Keyhole Limpet Hemocyanin
Dec 18, 2018: Corbus Pharmaceuticals announces Issuance of Composition of Matter Patent related to Lenabasum
Dec 17, 2018: Corbus Pharmaceuticals initiates “DETERMINE” phase 3 study in Dermatomyositis
Sep 20, 2018: Corbus Pharmaceuticals provides update on Lenabasum
Jul 25, 2018: Corbus Pharmaceuticals to Commence Phase 3 Study of Lenabasum for the Treatment of Rare Autoimmune Disease Dermatomyositis
Jul 20, 2018: Corbus Pharmaceuticals receives FDA Orphan Drug Designation for Lenabasum for the treatment of Dermatomyositis
Jun 06, 2018: GNI Group Initiates Etuary Phase III Trial in China for CTD-ILD
Apr 26, 2018: Corbus Pharmaceuticals to Present at the Deutsche Bank 43rd Annual Health Care Conference
Mar 02, 2018: Corbus Pharmaceuticals to Present at the Cowen & Co. 38th Annual Health Care Conference
Feb 06, 2018: Corbus Pharmaceuticals to Present at the 7th Annual LEERINK Partners Global Healthcare Conference
Nov 27, 2017: Corbus Pharmaceuticals Expands Intellectual Property Portfolio with Patent Issuance Covering the Use of Anabasum for the Treatment of Rare Fibrotic Diseases
Oct 31, 2017: Corbus Pharmaceuticals Announces New Patent Issuance Covering the Use of Anabasum for the Treatment of Inflammatory Diseases
Oct 19, 2017: Corbus Pharmaceuticals Reports Positive Topline Results from Phase 2 Study in Rare Autoimmune Disease Dermatomyositis
Jul 19, 2017: Neovacs Announces FDA Acceptance of a New IND to Expand in U.S. IFN-alpha Kinoid Clinical Development Program in Dermatomyositis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Dermatomyositis, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Dermatomyositis - Pipeline by Biocon Ltd, H2 2019
Dermatomyositis - Pipeline by Bristol-Myers Squibb Co, H2 2019
Dermatomyositis - Pipeline by Chugai Pharmaceutical Co Ltd, H2 2019
Dermatomyositis - Pipeline by Corbus Pharmaceuticals Inc, H2 2019
Dermatomyositis - Pipeline by CSL Ltd, H2 2019
Dermatomyositis - Pipeline by Eli Lilly and Co, H2 2019
Dermatomyositis - Pipeline by GNI Group Ltd, H2 2019
Dermatomyositis - Pipeline by Hope Pharmaceuticals Inc, H2 2019
Dermatomyositis - Pipeline by Johnson & Johnson, H2 2019
Dermatomyositis - Pipeline by Kezar Life Sciences Inc, H2 2019
Dermatomyositis - Pipeline by Neovacs SA, H2 2019
Dermatomyositis - Pipeline by NovelMed Therapeutics Inc, H2 2019
Dermatomyositis - Pipeline by Octapharma AG, H2 2019
Dermatomyositis - Pipeline by Pfizer Inc, H2 2019
Dermatomyositis - Pipeline by ReveraGen BioPharma Inc, H2 2019
Dermatomyositis - Pipeline by Viela Bio Inc, H2 2019
Dermatomyositis - Dormant Projects, H2 2019
Dermatomyositis - Discontinued Products, H2 2019

List of Figures
Number of Products under Development for Dermatomyositis, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products by Top 10 Targets, H2 2019
Number of Products by Stage and Top 10 Targets, H2 2019
Number of Products by Top 10 Mechanism of Actions, H2 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Biocon Ltd
  • Bristol-Myers Squibb Co
  • Chugai Pharmaceutical Co Ltd
  • Corbus Pharmaceuticals Inc
  • CSL Ltd
  • Eli Lilly and Co
  • GNI Group Ltd
  • Hope Pharmaceuticals Inc
  • Johnson & Johnson
  • Kezar Life Sciences Inc
  • Neovacs SA
  • NovelMed Therapeutics Inc
  • Octapharma AG
  • Pfizer Inc
  • ReveraGen BioPharma Inc
  • Viela Bio Inc
Note: Product cover images may vary from those shown
Adroll
adroll